Skip to main content
Journal cover image

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.

Publication ,  Journal Article
Thompson, AJ; Fellay, J; Patel, K; Tillmann, HL; Naggie, S; Ge, D; Urban, TJ; Shianna, KV; Muir, AJ; Fried, MW; Afdhal, NH; Goldstein, DB ...
Published in: Gastroenterology
October 2010

BACKGROUND & AIMS: In a genome-wide association study of patients being treated for chronic hepatitis C, 2 functional variants in ITPA that cause inosine triphosphatase (ITPase) deficiency were shown to protect against ribavirin (RBV)-induced hemolytic anemia during early stages of treatment. We aimed to replicate this finding in an independent cohort from the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C and to investigate the effects of these variants beyond week 4. METHODS: Genetic material was available from 318 patients. The ITPA variants, rs1127354 (exon 2, P32T) and rs7270101 (intron 2, splice altering), were genotyped and tested for association with hemoglobin (Hb) reduction at week 4. An ITPase deficiency variable was defined that combined both ITPA variants according to documented effect on ITPase activity. We investigated the impact of ITPA variants on Hb levels over the course of therapy and on the need for RBV dose reduction. RESULTS: The final analysis included 304 patients with genotype 1 hepatitis C virus (167 white patients and 137 black patients). The polymorphisms rs1127354 and rs7270101 were associated with Hb reduction at week 4 (P = 3.1 × 10(-13) and 1.3 × 10(-3), respectively). The minor alleles of each variant protected against Hb reduction. Combining the variants into the ITPase deficiency variable strengthened the association (P = 2.4 × 10(-18)). The ITPase deficiency variable was associated with lower rates of anemia over the entire treatment period (48 weeks), as well as a lower rate of anemia-related RBV dose reduction (hazard ratio, 0.52; P = .0037). No association with sustained virological response was observed. CONCLUSIONS: Two polymorphisms that cause ITPase deficiency are strongly associated with protection from RBV-induced hemolytic anemia and decrease the need for RBV dose reduction.

Duke Scholars

Published In

Gastroenterology

DOI

EISSN

1528-0012

Publication Date

October 2010

Volume

139

Issue

4

Start / End Page

1181 / 1189

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Ribavirin
  • Pyrophosphatases
  • Polymorphism, Single Nucleotide
  • Middle Aged
  • Male
  • Humans
  • Genotype
  • Gastroenterology & Hepatology
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Thompson, A. J., Fellay, J., Patel, K., Tillmann, H. L., Naggie, S., Ge, D., … McHutchison, J. G. (2010). Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology, 139(4), 1181–1189. https://doi.org/10.1053/j.gastro.2010.06.016
Thompson, Alexander J., Jacques Fellay, Keyur Patel, Hans L. Tillmann, Susanna Naggie, Dongliang Ge, Thomas J. Urban, et al. “Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.Gastroenterology 139, no. 4 (October 2010): 1181–89. https://doi.org/10.1053/j.gastro.2010.06.016.
Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010 Oct;139(4):1181–9.
Thompson, Alexander J., et al. “Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.Gastroenterology, vol. 139, no. 4, Oct. 2010, pp. 1181–89. Pubmed, doi:10.1053/j.gastro.2010.06.016.
Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, Afdhal NH, Goldstein DB, McHutchison JG. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010 Oct;139(4):1181–1189.
Journal cover image

Published In

Gastroenterology

DOI

EISSN

1528-0012

Publication Date

October 2010

Volume

139

Issue

4

Start / End Page

1181 / 1189

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Ribavirin
  • Pyrophosphatases
  • Polymorphism, Single Nucleotide
  • Middle Aged
  • Male
  • Humans
  • Genotype
  • Gastroenterology & Hepatology
  • Female